Biomerieux (BIM.PA) Osake Kurssi
Biomerieux Kurssi
Liikevaihto on kasvanut 7,5 % vuodessa viimeisten 19 vuoden aikana 4,07 Mrd. EUR:een. Osakekohtainen tulos on kasvanut 7,2 % vuodessa viimeisten 19 vuoden aikana. Biomerieuxn nettomarginaali on nyt 9,8 %, laskenut 17,8 %:sta muutama vuosi sitten. Biomerieuxn osinkotuotto on tällä hetkellä noin 0,95 %. Jakosuhde on noin 27 % tuloksesta. Osinko on kasvanut 9,8 % vuodessa viimeisten 19 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 121,38 EUR, eli yli nykyhintaa 28,0 %. 17 analyytikosta 10 suosittaa ostoa — kokonaiskonsensus on Osta.
Biomerieux osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Biomerieux liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Biomerieux -osakkeesta
The business model of Biomerieux SA is focused on diagnostic solutions for infectious diseases and cancer. The company develops and manufactures in vitro diagnostic tests, instruments, and software that aid in detecting diseases and guiding patient treatment. Biomerieux's comprehensive portfolio caters to clinical laboratories, hospitals, and industrial microbiology laboratories globally. Their solutions include microbiology, immunoassays, molecular biology, and blood culture systems. By leveraging cutting-edge technologies, Biomerieux aims to improve patient outcomes and enhance public health through early and accurate diagnosis. With a strong emphasis on research and innovation, the company continues to lead in the field of clinical diagnostics, offering reliable and efficient solutions for healthcare professionals worldwide.
Biomerieux SA is primarily active in the diagnostics industry.
The main competitors of Biomerieux SA in the market include companies like Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, and QIAGEN N.V.
Biomerieux SA, a leading global player in the field of in vitro diagnostics, has a rich history and background. The company was founded in 1963 by Dr. Alain Merieux with a vision to improve public health and patient care. Over the years, Biomerieux has expanded its portfolio and expertise in microbiology, infectious diseases, and molecular diagnostics. With a strong commitment to innovation, the company has developed pioneering diagnostic solutions, including automated systems and reagents. Biomerieux serves various industries, including clinical laboratories, food testing, and pharmaceuticals, enabling timely and accurate disease detection and better treatment outcomes. With continuous research and development efforts, Biomerieux remains at the forefront of diagnostic solutions globally.
Biomerieux SA has achieved significant milestones throughout its history. The company has successfully developed and launched innovative diagnostic solutions for various diseases and conditions, contributing to improved patient care worldwide. Biomerieux SA also expanded its global presence by establishing strategic partnerships and acquiring complementary businesses. With a strong focus on research and development, the company has received numerous regulatory approvals for its diagnostic tests and devices. In addition, Biomerieux SA has garnered recognition for its commitment to sustainability and corporate social responsibility initiatives. These notable achievements highlight Biomerieux SA's dedication to advancing healthcare technology and delivering reliable diagnostic solutions.
Biomerieux SA is primarily present in countries and regions worldwide. With its global presence, Biomerieux has established a strong presence in numerous countries, including but not limited to, France, the United States, China, Brazil, India, and Japan. The company's operations span across these regions, allowing it to deliver its innovative diagnostic solutions and laboratory services to healthcare institutions, research facilities, and other related entities. Biomerieux's commitment to expanding its network ensures that its products and expertise are accessible to diverse populations, ultimately contributing to improved healthcare outcomes globally.
Biomerieux SA is committed to upholding strong values and a distinct corporate philosophy. The company prioritizes innovation, aiming to develop and provide cutting-edge solutions in the field of in vitro diagnostics. With a focus on healthcare, Biomerieux SA values quality, excellence, and patient well-being. By leveraging their expertise in microbiology, the company strives to improve public health worldwide. Biomerieux SA also emphasizes collaboration, teamwork, and ethical conduct among its employees. With a dedication to sustainable growth and a global outlook, Biomerieux SA continues to contribute to the advancement of diagnostic testing and improving patient outcomes.
Analyytikot asettavat tällä hetkellä Biomerieux-osakkeelle keskimääräisen tavoitehinnan 121,10 EUR (mediaani: 121,38 EUR), mikä merkitsee +27,7 % viimeisimpään hintaan verrattuna. Konsensus perustuu 17 analyytikkoarvioon.
17 analyytikkoa arvioi tällä hetkellä Biomerieux-osaketta: 10 suosittaa ostoa, 7 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Biomerieux-yhtiöltä 4,14 Mrd. EUR liikevaihtoa ja 4,41 EUR osakekohtaista tulosta.
Biomerieux-osake (BIM.PA) on listattuna 8 pörssissä, muun muassa: London (0RUG.L), Frankfurt (EYWN.F), München (EYWN.MU), Düsseldorf (EYWN.DU), Wien (BIM.VI), Paris (BIM.PA).
The company Biomerieux SA was founded in 1963 and is headquartered in France. It is a leading manufacturer of in vitro diagnostics (IVD) and specializes in the development and production of solutions for the diagnosis of infectious diseases. Biomerieux operates several subsidiaries worldwide and employs approximately 12,000 people. Biomerieux's business model includes several divisions, including clinical diagnostics, industrial microbiology, food and water diagnostics, and veterinary diagnostics. In clinical diagnostics, the company offers a wide range of solutions for the diagnosis of infectious diseases. This includes test kits for the identification of bacteria, viruses, and fungi, PCR tests, and microbiology systems for determining antibiotic susceptibility. In industrial microbiology, Biomerieux specializes in the development of systems for the rapid identification of microorganisms in the food and beverage industry. The company also provides solutions for water quality control and industrial processes. The tests range from detecting contaminants in water samples to monitoring cleanroom conditions in the pharmaceutical industry. In the field of food and water diagnostics, Biomerieux is a global leader in the development of innovative solutions for detecting foodborne infections and toxins. The company offers a wide range of tests for monitoring food and drinking water. This also includes tests for controlling milk cultures and their fermentation. Veterinary diagnostics is another important area for Biomerieux. The company has developed a range of test kits for the diagnosis of animal diseases, including tests for the detection of infectious diseases in livestock. Biomerieux has become a key player in the field of medical diagnostics. The company invests heavily in research and development to develop new solutions for the diagnosis of infectious diseases. In addition, Biomerieux places great value on collaboration with other companies and research institutions to further improve the field of medical diagnostics. Overall, Biomerieux SA offers a wide range of solutions for the diagnosis of infectious diseases. The company is a leader in the fields of clinical diagnostics, industrial microbiology, food and water diagnostics, and veterinary diagnostics. Biomerieux continues to invest in research and development to develop innovative solutions that further improve the diagnosis of infectious diseases.
odotettu liikevaihto Biomerieux on 4,14 Mrd. EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Biomerieux on 524,98 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Biomerieux:n hinta-voitto-suhde (P/E) on tällä hetkellä 21,50. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Biomerieux-osakkeen arvostusta.
Biomerieux:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,72. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Biomerieux-osakkeen arvostuskennuslukuna.
Biomerieux:n Eulpool-laatuscore on 5/10.
Biomerieux:n ISIN on FR0013280286. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Biomerieux:n WKN on A2DXZH. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Biomerieux:n ticker on BIM.PA. Tämä pörssinoteeraus käytetään Biomerieux-osakkeiden kauppaan pörssissä.
Biomerieux osake
Biomerieux vertaisryhmä
Biomerieux Ticker
Biomerieux FIGI
Kaikki tunnusluvut ja syvällinen analyysi Biomerieux:sta
Meidän osakeanalyysimme Biomerieux-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Biomerieux:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: